First European phase II trial of intravenous (iv) cetuximab (Cet) and hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil and oxaliplatin in patients with unresectable liver metastases from wt KRAS colorectal cancer (CRC) after systemic therapy failure (OPTILIV, NCT00852228)

被引：0

作者：

Levi, Francis

Ducreux, Michel

Hebbar, Mohamed

Rougier, Philippe

Focan, C. N. J.

Guimbaud, Rosine

Carvalho, Carlos

Tumolo, Salvatore

Innominato, Pasquale F.

Ajavon, Yves

Castaing, Denis

De Baere, Thierry

Karaboue, Abdoulaye

Lepere, Celine

Boige, Valerie

Proux, Laetitia

Adam, Rene

Bouchahda, Mohamed

机构：

[1] Hop Paul Brousse, Dept Med Oncol, INSERM U776, Villejuif, France

[2] Inst Gustave Roussy, Villejuif, France

[3] Ctr Hosp Reg & Univ Lille, Hop Huriez, Med Oncol Unit, F-59037 Lille, France

[4] European Hosp George Pompidou, Paris, France

[5] CHC Clin St Joseph, Liege, Belgium

[6] Univ Hosp Purpan, Toulouse, France

[7] Hosp Fernando Fonesca Amadora, Med Oncol Unit, Amadora, Portugal

[8] Santa Maria Degli Angeli Gen Hosp, Pordenone, Italy

[9] Hop Paul Brousse, Inserm U776, Dept Cancerol, Villejuif, France

[10] Hop Paul Brousse, Serv Radiol, Villejuif, France

[11] Hop Paul Brousse, Hepatobiliary Ctr, Villejuif, France

[12] Hop Paul Brousse, INSERM U776, Villejuif, France

[13] Inst Gustave Roussy, Serv Hepatogastroenterol, Villejuif, France

[14] CRESGE, Lille, France

[15] Hop Paul Brousse, Hepatobiliary Ctr, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3547

引用

页数：1